AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
常规交易时段
US$36.61
−US$0.50 · -1.35%
盘中时间采用ET。市场数据可能有所延迟。
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
日内区间
当前US$36.61
52周区间
当前US$36.61
盘中时间采用ET。市场数据可能有所延迟。
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
日内区间
当前US$36.61
52周区间
当前US$36.61
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2.25亿 USD | 1.87亿 USD | 1.59亿 USD | 1.39亿 USD | 1.27亿 USD |
| 销货成本 | 5785.5万 USD | 4536.1万 USD | 3714.3万 USD | 2977.5万 USD | 2293.1万 USD |
| 毛利 | 1.67亿 USD | 1.42亿 USD | 1.22亿 USD | 1.09亿 USD | 1.04亿 USD |
| 研究与开发 | 3288.5万 USD | 2776.7万 USD | 2733.9万 USD | 2562.7万 USD | 2417.7万 USD |
| 销售、一般及管理费用 | 1.42亿 USD | 1.17亿 USD | 1.16亿 USD | 1.13亿 USD | 1.06亿 USD |
| 营业费用 | 1.75亿 USD | 1.45亿 USD | 1.43亿 USD | 1.39亿 USD | 1.3亿 USD |
| 利息支出 | 770.2万 USD | 820.6万 USD | 283.5万 USD | 62.4万 USD | 135.6万 USD |
| 折旧和摊销 | 819.3万 USD | 783.7万 USD | 555.3万 USD | 485.3万 USD | 474.1万 USD |
| 营业利润 | −784.9万 USD | −328.7万 USD | −2146.2万 USD | −2970.7万 USD | −2541.6万 USD |
| 净利润 | −1570.3万 USD | −996.4万 USD | −2171.6万 USD | −2894.8万 USD | −2698.5万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$53.17
上涨空间 45.23%年度分割调整后的每股现金分配。
US$1.00
2010年(完整年度)+2296.8% 自从 1992
US$0.0417
1,992
US$0.06
2,005
US$1.00
2,010
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2010年1月27日 | US$1.00Special | 2010年1月29日 | 2010年2月12日 |
股息 | 2005年2月23日 | US$0.06Special | — | — |
股息 | 1992年7月10日 | US$0.0417Special | — | — |
除息 2010年1月27日
US$1.00
Special
2010年1月29日登记 · 支付日 2010年2月12日
除息 2005年2月23日
US$0.06
Special
除息 1992年7月10日
US$0.0417
Special
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI8123.7万0.00%2.3万亿 USD0.03%US$380.88-0.18%
iShares Russell 2000 ETFIWM5074.09万0.07%787.4亿 USD0.19%US$276.22-0.60%
Vanguard Extended Market ETFVXF3137.78万0.03%954亿 USD0.05%US$232.08-0.62%
iShares Russell 2000 Growth ETFIWO1812.92万0.13%139.17亿 USD0.24%US$350.9-0.79%
Vanguard Russell 2000 ETFVTWO1535.93万0.08%180亿 USD0.06%US$111.55-0.64%
Schwab U.S. Small-Cap ETFSCHA1147.86万0.05%217.13亿 USD0.03%US$32.485-0.54%
Fidelity Enhanced Small Cap ETFFESM1104.86万0.17%64.1亿 USD0.28%US$45.015-0.50%
iShares U.S. Medical Devices ETFIHI1076.56万0.30%35.74亿 USD0.37%US$52.59-0.38%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
Vanguard Russell 2000 ETFVTWO
Schwab U.S. Small-Cap ETFSCHA
Fidelity Enhanced Small Cap ETFFESM
iShares U.S. Medical Devices ETFIHIAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。